<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">MICAFUNGIN</span><br/>(my-ca-fun'gin)<br/><span class="topboxtradename">Mycamine<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antibiotic</span>; <span class="classification">echinocandin, antifungal </span><br/><b>Prototype: </b>Caspofungin<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>50 mg vial </p>
<h1><a name="action">Actions</a></h1>
<p>Micafungin is an antifungal agent that inhibits the synthesis of glucan, an essential component of fungal cell walls.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Micafungin does not allow Candida fungi to replicate.</p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of patients with esophageal candidiasis, and for prophylaxis of <i>Candida</i> infections in patients undergoing hematopoietic stem cell transplantation. Susceptible organisms include <i>C. albicans</i>, <i>C. glabrata</i>, <i>C. krusei</i>, <i>C. parapsilosis</i>, and <i>C. tropicalis</i>.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Treatment of pulmonary <i>Aspergillus</i> infection
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to any component in micafungin. Safety and efficacy in children are unknown.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hepatic and renal dysfunction; pregnancy (category C); lactation; older adult.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Esophageal Candidiasis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 150 mg/d over 1 h<br/><br/><span class="indicationtitle">Candidiasis Prophylaxis in Patients Undergoing Hematopoietic Stem Cell Transplantation</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 50 mg/d over 1 h <br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">IV Infusion:</span> Reconstitute the 50 mg vial with 5 mL NS (without a bacteriostatic agent) to yield 10 mg/mL. Gently swirl, but do not shake,
                  to dissolve. Solution should be clear. For <i>Candida</i> prophylaxis, add contents of one reconstituted vial to 100 mL NS. For esophageal candidiasis, add contents of three reconstituted
                  vials to 100 mL NS.   
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">IV Infusion:</span> Give slowly over 1 h. Flush existing IV line with NS before/after infusion. Protect IV solution from light.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> Do not mix or coinfuse with any other medications. 
               </p>
<ul>
<li>Store reconstituted vial and IV solution for up to 24 h at 25° C (77° F). Protect from light.</li>
</ul>
</td>
</tr>
</table>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span>
<span class="speceff-common">Headache,</span> dizziness, somnolence. <span class="typehead">CV:</span> Flushing, hypertension, phlebitis. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea, vomiting, diarrhea</span>, abdominal pain. <span class="typehead">Hematologic/Lymphatic:</span> Anemia, hemolytic anemia, leukemia, neutropenia, thrombocytopenia. <span class="typehead">Hepatic:</span> Elevated liver enzymes, jaundice. <span class="typehead">Metabolic:</span> Hypocalcemia, hypokalemia, hypomagnesemia. <span class="typehead">Skin:</span> Pruritis, rash. <span class="typehead">Body as a Whole:</span> Injection site pain, pyrexia, rigors. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Micafungin increases levels of <b>sirolimus</b> and <b>nifedipine</b>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Distribution:</span> 99% protein bound. <span class="typehead">Metabolism:</span> Biotransformation primarily in the liver. <span class="typehead">Elimination:</span> Fecal (major) and renal. <span class="typehead">Half-Life:</span> 1417 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for S&amp;S of hypersensitivity during IV infusion; frequently monitor IV site for thrombophlebitis.</li>
<li>Monitor for S&amp;S of hemolytic anemia (i.e., jaundice).</li>
<li>Lab tests: Periodic LFTs, kidney function tests, serum electrolytes, and CBC.</li>
<li>Monitor blood levels of sirolimus or nifedipine with concurrent therapy. If sirolimus or nifedipine toxicity occurs, dosages
            of these drugs should be reduced.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report immediately any of the following: facial swelling, wheezing, difficulty breathing or swallowing, tightness in chest,
            rash, hives, itching, or sensation of warmth.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>